Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Niagen Bioscience (NAGE) over the last 11 years, with Q3 2025 value amounting to -$12000.0.

  • Niagen Bioscience's Asset Writedowns and Impairment fell 20000.0% to -$12000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 343717.95%. This contributed to the annual value of -$1.3 million for FY2024, which is 23485.48% down from last year.
  • Latest data reveals that Niagen Bioscience reported Asset Writedowns and Impairment of -$12000.0 as of Q3 2025, which was down 20000.0% from $89000.0 recorded in Q2 2025.
  • Niagen Bioscience's Asset Writedowns and Impairment's 5-year high stood at $400000.0 during Q2 2023, with a 5-year trough of -$1.4 million in Q4 2024.
  • For the 5-year period, Niagen Bioscience's Asset Writedowns and Impairment averaged around -$78947.4, with its median value being $14000.0 (2021).
  • As far as peak fluctuations go, Niagen Bioscience's Asset Writedowns and Impairment skyrocketed by 810000.0% in 2023, and later tumbled by 725263.16% in 2024.
  • Over the past 5 years, Niagen Bioscience's Asset Writedowns and Impairment (Quarter) stood at $198000.0 in 2021, then tumbled by 82.32% to $35000.0 in 2022, then plummeted by 45.71% to $19000.0 in 2023, then crashed by 7252.63% to -$1.4 million in 2024, then soared by 99.12% to -$12000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at -$12000.0 for Q3 2025, versus $89000.0 for Q2 2025 and -$1.3 million for Q1 2025.